(1)          Sigismund S, Avanzato D and Lanzetti L. Emerging functions of the EGFR in cancer. Mol. Oncol. (2018) 12: 3-20.

(2)          Mitchell RA, Luwor RB and Burgess AW. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics. Exp. Cell Res. (2018) 371: 1-19.

(3)          Wang Z. ErbB Receptors and Cancer. Methods Mol. Biol. (2017) 1652: 3-35.

(4)          Pool M, de Boer HR, Hooge MNL, van Vugt M and de Vries EGE. Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics (2017) 7: 2111-2133.

(5)          An Z, Aksoy O, Zheng T, Fan QW and Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene (2018) 37: 1561-1575.

 (6)          Liu X, Wang P, Zhang C and Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget (2017) 8: 50209-50220.

 (7)          Wee P and Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel) (2017) 9.

(8)          Byeon HK, Ku M and Yang J. Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Exp. Mol. Med. (2019) 51: 1-14.

 (9)          Matsumoto K, Umitsu M, De Silva DM, Roy A and Bottaro DP. Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci. (2017) 108: 296-307.

 (10)        Rebuzzi SE, Alfieri R, La Monica S, Minari R, Petronini PG and Tiseo M. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. Crit. Rev. Oncol. Hematol. (2020) 146: 102820.

 (11)        Rotow J and Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer (2017) 17: 637-658.

(12)        Nami B, Maadi H and Wang Z. The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation. Cancers (Basel) (2019) 11.

 (13)        Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Jänne PA, Crews CM and Gray NS. Development of small molecules targeting the pseudokinase Her3. Bioorg Med Chem Lett (2015) 25: 3382-3389.

(14)        Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim T, Marto JA, Jänne PA, Crews CM and Gray NS. Pharmacological targeting of the pseudokinase Her3. Nat. Chem. Biol. (2014) 10: 1006-1012.

(15)        Claus J, Patel G, Ng T and Parker PJ. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy. Biochem. Soc. Trans. (2014) 42: 831-836.

(16)        Li QH, Wang YZ, Tu J, Liu CW, Yuan YJ, Lin R, He WL, Cai SR, He YL and Ye JN. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol Rep (Oxf) (2020) 8: 179-191.

 (17)        Dieci MV, Miglietta F, Griguolo G and Guarneri V. Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. Cancer Treat. Rev. (2020) 88: 102064.

(18)        Maennling AE, Tur MK, Niebert M, Klockenbring T, Zeppernick F, Gattenlöhner S, Meinhold-Heerlein I and Hussain AF. Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers (Basel) (2019) 11.

(19)        Arienti C, Pignatta S and Tesei A. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Front. Oncol. (2019) 9: 1308.

(20)        Liu X, Liu S, Lyu H, Riker AI, Zhang Y and Liu B. Development of Effective Therapeutics Targeting HER3 for Cancer Treatment. Biol. Proced. Online (2019) 21: 5.

(21)        Karachaliou N, Lazzari C, Verlicchi A, Sosa AE and Rosell R. HER3 as a Therapeutic Target in Cancer. Biodrugs (2017) 31: 63-73.

(22)        Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C and Gullick WJ. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene (1992) 7: 1273-1278.

(23)        Srinivasan R, Poulsom R, Hurst HC and Gullick WJ. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J. Pathol. (1998) 185: 236-245.

 (24)        Bae SY, La Choi Y, Kim S, Kim M, Kim J, Jung SP, Choi MY, Lee SK, Kil WH, Lee JE and Nam SJ. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. Breast Cancer Res. Treat. (2013) 139: 741-750.

(25)        Ho-Pun-Cheung A, Bazin H, Boissière-Michot F, Mollevi C, Simony-Lafontaine J, Landas E, Bleuse JP, Chardès T, Prost JF, Pèlegrin A, Jacot W, Mathis G and Lopez-Crapez E. Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples. Br. J. Cancer (2020) 122: 397-404.

(26)        Cho HS and Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether. Science (2002) 297: 1330-1333.

(27)        Kani K, Park E and Landgraf R. The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation. Biochemistry (2005) 44: 15842-15857.

(28)        Brand TM, Iida M, Luthar N, Wleklinski MJ, Starr MM and Wheeler DL. Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3. PLoS One (2013) 8: e71518.

(29)        Choi BK, Cai X, Yuan B, Huang Z, Fan X, Deng H, Zhang N and An Z. HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways. Protein Cell (2012) 3: 781-789.

(30)        Büttner R, Berndt A, Valkova C, Richter P, Korn A, Kosan C and Liebmann C. Myofibroblasts have an impact on expression, dimerization and signaling of different ErbB receptors in OSCC cells. J. Recept. Signal Transduct. Res. (2017) 37: 25-37.

31)        Collier TS, Diraviyam K, Monsey J, Shen W, Sept D and Bose R. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. J. Biol. Chem. (2013) 288: 25254-25264.

(32)        Miyamoto Y, Torii T, Tanoue A, Kawahara K, Arai M, Tsumura H, Ogata T, Nagao M, Terada N, Yamamoto M, Takashima S and Yamauchi J. Neuregulin-1 type III knockout mice exhibit delayed migration of Schwann cell precursors. Biochem Biophys Res Commun (2017) 486: 506-513.

(33)        Espinosa-Medina I, Jevans B, Boismoreau F, Chettouh Z, Enomoto H, Müller T, Birchmeier C, Burns AJ and Brunet JF. Dual origin of enteric neurons in vagal Schwann cell precursors and the sympathetic neural crest. Proc. Natl. Acad. Sci. U. S. A. (2017) 114: 11980-11985.

(34)        Steiner H, Blum M, Kitai ST and Fedi P. Differential expression of ErbB3 and ErbB4 neuregulin receptors in dopamine neurons and forebrain areas of the adult rat. Exp. Neurol. (1999) 159: 494-503.

 (35)        Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A, Burdon P, Montagut C and Laurent-Puig P. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. Drugs (2019) 79: 1375-1394.

(36)        Black LE, Longo JF and Carroll SL. Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia. Am. J. Pathol. (2019) 189: 1898-1912.

 (37)        Citri A, Skaria KB and Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp. Cell Res. (2003) 284: 54-65.

(38)        Ståhl S, Gräslund T, Eriksson Karlström A, Frejd FY, Nygren P and Löfblom J. Affibody Molecules in Biotechnological and Medical Applications. Trends Biotechnol. (2017) 35: 691-712.

(39)        Frejd FY and Kim KT. Affibody molecules as engineered protein drugs. Exp. Mol. Med. (2017) 49: e306.

(40)        Tolmachev V and Orlova A. Affibody Molecules as Targeting Vectors for PET Imaging. Cancers (Basel) (2020) 12.

(41)        Malm M, Kronqvist N, Lindberg H, Gudmundsdotter L, Bass T, Frejd FY, Höidén-Guthenberg I, Varasteh Z, Orlova A, Tolmachev V, Ståhl S and Löfblom J. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One (2013) 8: e62791.

(42)        Orlova A, Malm M, Rosestedt M, Varasteh Z, Andersson K, Selvaraju RK, Altai M, Honarvar H, Strand J, Ståhl S, Tolmachev V and Löfblom J. Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule. Eur. J. Nucl. Med. Mol. Imaging (2014) 41: 1450-1459.

(43)        Rosestedt M, Andersson KG, Rinne SS, Leitao CD, Mitran B, Vorobyeva A, Ståhl S, Löfblom J, Tolmachev V and Orlova A. Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. Sci. Rep. (2019) 9: 6779.

(44)        Rinne SS, Xu T, Dahlsson Leitao C, Ståhl S, Löfblom J, Orlova A, Tolmachev V and Vorobyeva A. Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. Int. J. Mol. Sci. (2020) 21: 1312.

(45)        Thomas M, Patel KK, Peri-Okonny P, Sperry BW, McGhie AI, Badarin FA, Saeed IM, Kennedy KF, Chan P, Spertus JA, Thompson RC and Bateman TM. Stress myocardial perfusion imaging in patients presenting with syncope: Comparison of PET vs. SPECT. J. Nucl. Cardiol. (2020).

(46)        Spencer SS, Theodore WH and Berkovic SF. Clinical applications: MRI, SPECT, and PET. Magn. Reson. Imaging (1995) 13: 1119-1124.

(47)        Rosestedt M, Andersson KG, Mitran B, Tolmachev V, Löfblom J, Orlova A and Ståhl S. Affibody-mediated PET imaging of HER3 expression in malignant tumours. Sci. Rep. (2015) 5: 15226.

(48)        Rinne SS, Dahlsson Leitao C, Gentry J, Mitran B, Abouzayed A, Tolmachev V, Ståhl S, Löfblom J and Orlova A. Increase in negative charge of (68)Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. Sci. Rep. (2019) 9: 17710-17710.

(49)        Larimer BM, Phelan N, Wehrenberg-Klee E and Mahmood U. Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide. Mol. Imaging Biol. (2018) 20: 300-308.

(50)        Rinne SS, Dahlsson Leitao C, Saleh-Nihad Z, Mitran B, Tolmachev V, Ståhl S, Löfblom J and Orlova A. Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. Int. J. Mol. Sci. (2020) 21: 1972.

(51)        Perrin DM. Organotrifluoroborates as prosthetic groups for Single-Step F18-Labeling of Complex Molecules. Curr. Opin. Chem. Biol. (2018) 45: 86-94.

(52)        Schirrmacher R, Wängler B, Bailey J, Bernard-Gauthier V, Schirrmacher E and Wängler C. Small Prosthetic Groups in (18)F-Radiochemistry: Useful Auxiliaries for the Design of (18)F-PET Tracers. Semin. Nucl. Med. (2017) 47: 474-492.

(53)        Fersing C, Bouhlel A, Cantelli C, Garrigue P, Lisowski V and Guillet B. A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [(18)F]fluoride: Will [(18)F]AlF Replace (68)Ga for Metal Chelate Labeling? Molecules (2019) 24.

(54)        Kumar K and Ghosh A. (18)F-AlF Labeled Peptide and Protein Conjugates as Positron Emission Tomography Imaging Pharmaceuticals. Bioconjug. Chem. (2018) 29: 953-975.

(55)        Da Pieve C, Allott L, Martins CD, Vardon A, Ciobota DM, Kramer-Marek G and Smith G. Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors. Bioconjug. Chem. (2016) 27: 1839-1849.

(56)        Yuan Q, Furukawa T, Tashiro T, Okita K, Jin Z-H, Aung W, Sugyo A, Nagatsu K, Endo H and Tsuji AB. Immuno-PET imaging of HER3 in a model in which HER3 signaling plays a critical role. PLoS One (2015) 10: e0143076.

 (57)        Alsaid H, Skedzielewski T, Rambo MV, Hunsinger K, Hoang B, Fieles W, Long ER, Tunstead J, Vugts DJ and Cleveland M. Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice. PLoS One (2017) 12: e0176075.

(58)        Menke-van der Houven van Oordt CW, McGeoch A, Bergstrom M, McSherry I, Smith DA, Cleveland M, Al-Azzam W, Chen L, Verheul H, Hoekstra OS, Vugts DJ, Freedman I, Huisman M, Matheny C, van Dongen G and Zhang S. Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2019) 60: 902-909.

(59)        Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, Hopfner K-P, Niederfellner G and Bossenmaier B. RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation. Cancer Res. (2013) 73: 5183.

(60)        Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MHG, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JHM, Weisser M and Lassen UN. First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. Clinical Cancer Research (2016) 22: 877.

(61)        Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, de Jong JR, Gietema JA, Schröder CP, Thomas M, Jacob W, Abiraj K, Adessi C, Meneses-Lorente G, James I, Weisser M, Brouwers AH and de Vries EGE. 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. Clin Cancer Res (2017) 23: 6128-6137.

(62)        Augello G, Emma MR, Cusimano A, Azzolina A, Mongiovì S, Puleio R, Cassata G, Gulino A, Belmonte B, Gramignoli R, Strom SC, McCubrey JA, Montalto G and Cervello M. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. Int. J. Cancer (2019) 144: 2613-2624.

(63)        Ishikawa C, Senba M and Mori N. Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma. Oncol. Lett. (2016) 12: 387-392.

(64)        Martins CD, Da Pieve C, Burley TA, Smith R, Ciobota DM, Allott L, Harrington KJ, Oyen WJG, Smith G and Kramer-Marek G. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. Clin Cancer Res (2018) 24: 1853-1865.

(65)        Pool M, Kol A, de Jong S, de Vries EGE, Lub-de Hooge MN and Terwisscha van Scheltinga AGT. (89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment. MAbs (2017) 9: 1370-1378.

(66)        De Pauw I, Wouters A, Van den Bossche J, Deschoolmeester V, Baysal H, Pauwels P, Peeters M, Vermorken JB and Lardon F. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. Cancer Biother Radiopharm (2017) 32: 229-238.

(67)        Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A and Clement PM. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer (2016) 122: 3803-3811.

(68)        Schaefer G, Haber L, Crocker Lisa M, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee Chingwei V, Stawicki S, Clark R, Fields C, Lewis Phillips Gail D, Prell Rodney A, Danilenko Dimitry M, Franke Y, Stephan J-P, Hwang J, Wu Y, Bostrom J, Sliwkowski Mark X, Fuh G and Eigenbrot C. A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies. Cancer Cell (2011) 20: 472-486.

(69)        Bourillon L, Demontoy S, Lenglet A, Zampieri A, Fraisse J, Jarlier M, Boissière-Michot F, Perrochia H, Rathat G, Garambois V, Bonnefoy N, Michaud H-A, Chardès T, Tosi D, Pèlegrin A, Azria D, Larbouret C and Bourgier C. Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells. International Journal of Radiation Oncology*Biology*Physics (2020) 106: 1039-1051.

(70)        Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A and Baselga J. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clinical Cancer Research (2015) 21: 2462.

(71)        McKnight BN, Kuda-Wedagedara ANW, Sevak KK, Abdel-Atti D, Wiesend WN, Ku A, Selvakumar D, Carlin SD, Lewis JS and Viola-Villegas NT. Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). Sci. Rep. (2018) 8: 9043.

(72)        Warnders FJ, Terwisscha van Scheltinga AGT, Knuehl C, van Roy M, de Vries EFJ, Kosterink JGW, de Vries EGE and Lub-de Hooge MN. Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of (89)Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging. J. Nucl. Med. (2017) 58: 1210-1215.

(73)        Wang M, Gao M and Zheng Q-H. The first radiosynthesis of [11C]AZD8931 as a new potential PET agent for imaging of EGFR, HER2 and HER3 signaling. Bioorg. Med. Chem. Lett. (2014) 24: 4455-4459.

(74)        Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, Kaplan R, Quirke P, Richman S, Samuel L, Seligmann J, Seymour M, Shiu KK, Wasan H, Wilson R and Maughan T. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. The lancet. Gastroenterology & hepatology (2018) 3: 162-171.

(75)        Barlaam B, Anderton J, Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Kettle JG, Kirk G, Klinowska T, Lambert-van der Brempt C, Trigwell C, Vincent J and Ogilvie D. Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. ACS Med. Chem. Lett. (2013) 4: 742-746.